PRIMARY CUTANEOUS ROSAI-DORFMAN DISEASE OF THE BACK: A RARE CASE REPORT

Thị Tuyết Hạnh Ngô, Văn Tấn Pham, Phạm Ngọc Châu Nguyễn , Thị Hòe Nguyễn , Hương Giang Trần

Main Article Content

Abstract

Rosai-Dorfman Disease is a rare, benign, and seft-limiting histiocytosis. The disease predominantly affects young adults, with a male predominance. It also predominantly affects the cervical lymph nodes, affecting only the skin very rarely, and is considered a distinctive clinicopathologic entity, easily misdiagnosed with other entities. We present a case of a 54-year-old man who had a bruised red nodular lesion on the right part of his back for about six months. The skin lesion was slowly progressing, painless, without fever. Histopathological evaluation revealed that the dermis and hypodermis consist of histiocytes containing “emperipolesis” (intact intracytoplasmic inflammatory cells). These histiocytes were expressed with CD68, S100, and Cyclin D1 but not with CD1a. The primary cutaneous Rosai-Dorfman disease was established based on the clinical and histopathological evidence obtained after excluding the disease’s involvement in the lymph nodes and other extranodal organs. After three months of post-surgery of completely removing the skin lesion, the wound exhibited good healing with no signs of disease recurrence noted.

Article Details

References

1. Yasodha Natkunam SR, Elizabeth G. Demicco, Bernhard Wilhelm, Heinrich Zelger, Bruce M Wenig, Ahmed Idbaih. Rosai-Dorfman Disease. In: John Chan SEC, ed. WHO Classification of Tumours Editorial Board Haematolymphoid tumours [Internet; beta version ahead of print]. 5 ed. International Agency for Research on Cancer; 2022. Accessed 2024 01 21. https://tumourclassification.iarc. who.int/chaptercontent/63/98
2. Bruce-Brand C, Schneider JW, Schubert P. Rosai-Dorfman disease: an overview. J Clin Pathol. Nov 2020;73(11):697-705. doi:10.1136/ jclinpath-2020-206733
3. Deen IU, Chittal A, Badro N, Jones R, Haas C. Extranodal Rosai-Dorfman Disease- a Review of Diagnostic Testing and Management. J Community Hosp Intern Med Perspect. 2022;12(2):18-22. doi:10.55729/2000-9666.1032
4. Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. Jun 2 2016;127(22):2672-81. doi:10.1182/blood-2016-01-690636
5. Brenn T, Calonje E, Granter SR, et al. Cutaneous rosai-dorfman disease is a distinct clinical entity. Am J Dermatopathol. Oct 2002;24(5): 385-91. doi:10.1097/00000372-200210000-00001
6. Sampaio R, Silva L, Catorze G, Viana I. Cutaneous Rosai-Dorfman disease: a challenging diagnosis. BMJ Case Rep. Feb 4 2021;14(2)doi: 10.1136/bcr-2020-239244
7. Gawdzik A, Ziarkiewicz-Wroblewska B, Chlebicka I, Jankowska-Konsur A, Szepietowski JC, Maj J. Cutaneous Rosai-Dorfman Disease: A Treatment Challenge. Dermatol Ther (Heidelb). Aug 2021;11(4):1443-1448. doi:10.1007/s13555-021-00557-1
8. Mizuta H, Nakano E, Yamazaki N. Primary Cutaneous Rosai-Dorfman Disease of the Scalp. Dermatol Pract Concept. Jan 2021;11(1): e2020086. doi:10.5826/dpc.1101a86